Myelofibrosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Mahshid |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}} | |||
==Overview== | |||
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. | |||
==Future or Investigational Therapies== | |||
*Future or investigational therapies involve: | |||
:*Immunomodulatory drugs<ref name="pmid30324817">{{cite journal |vauthors=Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M |title=Novel treatments to tackle myelofibrosis |journal=Expert Rev Hematol |volume=11 |issue=11 |pages=889–902 |date=November 2018 |pmid=30324817 |doi=10.1080/17474086.2018.1536538 |url=}}</ref> | |||
:*Histone deactylase inhibitors | |||
:*Second-generation Janus kinase 1/2 inhibitors | |||
==References== | ==References== | ||
Revision as of 01:32, 11 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis future or investigational therapies |
|
Myelofibrosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Myelofibrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT.
Future or Investigational Therapies
- Future or investigational therapies involve:
- Immunomodulatory drugs[1]
- Histone deactylase inhibitors
- Second-generation Janus kinase 1/2 inhibitors
References
- ↑ Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M (November 2018). "Novel treatments to tackle myelofibrosis". Expert Rev Hematol. 11 (11): 889–902. doi:10.1080/17474086.2018.1536538. PMID 30324817.